Cervical dystonia Market Analysis

Global Cervical Dystonia Market Overview

Cervical Dystonia Market Size was valued at USD 0.2 billion in 2022. The Cervical Dystonia market industry is projected to grow from USD 0.2146 Billion in 2023 to USD 0.377074 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.30% during the forecast period (2023 - 2032). Increased unmet healthcare needs, the surge in demand for advanced healthcare facilities, an increase in incidences of dystonia, and an increase in the prevalence of other neurological disorders having dystonia symptoms are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Cervical Dystonia Market Trends

• Rise in musculoskeletal disorders is driving the market growth

Musculoskeletal conditions are the leading contributors to disability worldwide, with lower back pain being the single leading cause of disability. Musculoskeletal conditions limit mobility and agility, leading to early retirement from work, reduced accumulated wealth, and reduced ability to participate in social roles. According to the World Health Organization (WHO), in a 2017 GBD study, musculoskeletal conditions were the highest contributors to  disability (accounting for 16% of all years lived with disability), and lower back pain was the single leading cause of disability. The prevalence of musculoskeletal conditions varies by age and diagnosis. 20% to 33% of people across the globe live with a painful musculoskeletal condition. This factor drives the market CAGR in the forecast period.

Additionally, the healthcare industry in emerging economies is developing significantly, owing to the rise in demand for enhanced healthcare services, significant investments by the government to improve healthcare infrastructure, and the development of the medical tourism industry in emerging countries. This will drive the market during the dystonia drugs market forecast period.

Though several factors boost the growth of the dystonia drugs market, factors such as the need for more awareness among the population in underdeveloped countries about Dystonia hinder the dystonia drugs market. In addition, the low purchasing power of people in underdeveloped and developing economies also restrains the market's growth in regions such as Asia-Pacific and LAMEA. However, technological advancements in pharmaceutical manufacturing and new product innovations and its launch and approval in the market are anticipated to drive the cervical dystonia market revenue during the forecast period.

Cervical Dystonia Market Segment Insights

Cervical Dystonia Drug Type Insights

Based on type, the cervical dystonia market segmentation includes torticollis, retrocollis, laterocollis, and others. The torticollis segment dominated the market because Torticollis is the most common type of cervical Dystonia, affecting approximately 90% of people with the condition. Moreover, Torticollis is more prevalent in females than males, with onset usually occurring in middle age, further expanding the potential patient pool.

Cervical Dystonia Treatment Insights

Based on treatment, the cervical dystonia market segmentation includes oral therapy, intravenous, surgery, and others. The oral therapy segment dominated the market, owing to the high permeability, drug solubility, and environmental stability in the gastrointestinal tract, along with the cost-effectiveness of the medications.

Cervical Dystonia End-User Insights

Based on end-user, the Cervical Dystonia market segmentation includes hospitals, clinics, and others. The hospital segment dominated the market due to the availability of specialized care units, experienced physicians, and advanced medical equipment. Hospitals are equipped to handle complex and severe cases of cervical Dystonia and provide multidisciplinary care to patients.

Figure1 Cervical Dystonia Market, by End-User,2022 & 2032 (USD billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Cervical Dystonia Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American cervical dystonia market will dominate due toincreased unmet healthcare needs. A surge in demand for advanced healthcare facilitieswill boost the market growth in this Region.

Further, the major countries studiedin the market reportare The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 Cervical Dystonia Market Share by Region 2022 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Cervical Dystonia market accounts for the second-largest market share due to increased investments by private players in the healthcare sector. Improved reimbursement policies are expected to propel the market in the Region. Further, the German Cervical Dystonia market held the largest market share, and the UK Cervical Dystonia market was the fastest-growing market in the European Region.

The Asia-Pacific Cervical Dystonia Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due tothe increase in the geriatric population in China and Japan, and the rapid growth of the pharmaceutical sector in India is likely to augment the market in this Region. Moreover, China’s Cervical Dystonia market held the largest market share, and the Indian Cervical Dystonia market was the fastest-growing market in the Asia-Pacific region.

Cervical Dystonia Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the Cervical Dystonia market grow even more. Market participants are also undertaking various strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The cervical dystonia industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Cervical Dystonia industry to benefit clients and increase the market sector. The Cervical Dystonia industry has offered some of the most significant medical advantages in recent years. Major players in the Cervical Dystonia market, including ALLERGAN (Ireland), Solstice Neurosciences LLC, Ipsen Biopharmaceuticals Inc. (France), Merz Inc (US), Addex Therapeutics (Switzerland), Revance Therapeutics Inc. (US)., and others, are attempting to increase market demand by investing in research and development operations.

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.Amneal Pharmaceuticals, Inc. announced the commercial launch of LYVISPAH, a baclofen oral granules specialty product approved by the U.S. Food and Drug Administration for treating spasticity related to multiple sclerosis and other spinal cord disorders.

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira, administered via injection. AbbVie announced a new co-development and license agreement with Gedeon Richter Plc. to research, develop, and commercialize novel dopamine receptor modulators for potentially treating neuropsychiatric diseases.

Key Companies in the cervical dystonia market include

• ALLERGAN (Ireland)


• Solstice Neurosciences LLC


• Ipsen Biopharmaceuticals Inc. (France)


• Merz Inc (US)


• Addex Therapeutics (Switzerland)


• Revance Therapeutics Inc (US)

Cervical dystonia Industry Developments

June 2022 Amneal Pharmaceuticals, Inc. announced the commercial launch of LYVISPAH, a baclofen oral granules specialty product approved by the U.S. Food and Drug Administration for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.

May 2020 AbbVie announced the acquisition of Allergan plc., a biopharmaceutical company offering products in immunology, hematologic, oncology, neuroscience, and Allergan aesthetics.

March 2022 AbbVie announced a new co-development and license agreement with Gedeon Richter Plc. to research, develop, and commercialize novel dopamine receptor modulators for potentially treating neuropsychiatric diseases.

Cervical Dystonia Market Segmentation

Cervical dystonia Drug Type Outlook

• Torticollis


• Retrocollis


• Laterocollis


• Others

Cervical Dystonia Treatment Outlook

• Oral Therapy


• Intravenous


• Surgery


• Others

Cervical dystonia End-User Outlook

• Hospital


• Clinics


• Others

Cervical dystonia Regional Outlook

• 
  North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America